Office of Technology Transfer – University of Michigan

Targeted Micelles with Lipophilic Drugs for Treating Cancer

Technology #6295

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Targeted Anti-Cancer Drug Delivery
Thomas Wang
Managed By
Tiefei Dong
Senior Licensing Specialist, Life Sciences 734-763-5332
Patent Protection
US Patent Pending

This technology enables the delivery of anti-cancer therapeutic agents specifically to colon cancer cells. Thus, it reduces toxic side effects associated with such therapeutics. Colon cancer is diagnosed in 1.36 million people globally every year and caused 52,000 deaths in USA in 2010. It is the second leading cause of cancer related death in the US. According to the American Cancer Society, the 5 year survival for some advanced stage colon cancers is < 50 %. This technology could thus improve survival in colon cancer patients.

Targeted Delivery Reduces Side Effects

The technology uses anti-cancer agents encapsulated in nanoscale micelles with targeting peptide sequences directed to colon cancer cells. Mice treated with the targeted anti-cancer micelles showed similar tumor regression when compared to free anti-cancer drug. However, mice treated with the targeted micelles showed less signs of kidney damage than mice treated with free drug. Moreover, the technology may also be applicable to other cancers when modified appropriately.


  • Targeted delivery of anti-cancer drugs
  • Targeted delivery of immunosupressants


  • Less toxic than free anti-cancer drugs
  • Higher concentration of drugs can be used